Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2011

View Archived Issues

Expanded data presented from ORACAL trial of oral versus nasal salmon calcitonin

Study identifies SNPs linked to remission and response to bupropion and placebo for depression

Orexigen receives design requirements from FDA for cardiovascular outcomes trial of Contrave

Results presented from ENCORE 301 study of exemestane plus entinostat in advanced breast cancer

Bristol-Myers Squibb and Ono enter agreement for Orencia and BMS-936558/ONO-4538

Findings disclosed from post hoc subanalysis of SYNCHRONY study

Cyclic lipopeptide shows promise to treat CDI-associated diarrhea in phase II trial

New phase I data disclosed on Pennvax-B HIV vaccine plus Genevax-IL12

European Commission approves Orion's sedative dexdor

Promising results reported on ProtoKinetix antiaging glycopeptide

Enrollment begins in phase III TOviTO program

OX-219 shows promise in patients with opioid dependence

European Commission approves Incivo

University of Pittsburgh presents new anticancer agents

ARIAD Pharmaceuticals advances phase I/II AP-26113 trial

Boehringer Ingelheim discloses novel Mnk inhibitors

Novel anticancer furoxan derivatives synthesized

New histone deacetylase inhibitors prepared by Millennium Pharmaceuticals

Aragon Pharmaceuticals describes new androgen receptor ligands

Nihon Medi-Physics begins phase III trial of imaging agent NMA-78

Repros Therapeutics' study of low-dose oral Proellex advances

Ariel Pharmaceuticals in-licenses lead product for acute migraine from BTG

Trident Pharmaceuticals' HF-1020 enters first-in-human trial

MSD launches Cubicin in Japan

European orphan drug designation granted to Pfizer's TB product candidate

F-647 approved in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...